- Research
- Open access
- Published:
A rare nonsynonymous variant in the lipid metabolic gene HELZ2 related to primary biliary cirrhosis in Chinese Han
Allergy, Asthma & Clinical Immunology volume 12, Article number: 14 (2016)
Abstract
Background
Several genome-wide association studies of primary biliary cirrhosis (PBC) in European and Japanese origins have shown significant association of dozens of genetic loci contributive to the susceptibility of PBC. Most of the loci were related to immune response pathway. In this study, we tested whether the lipid metabolic gene HELZ2 was associated with the pathogenesis of PBC.
Methods
In 586 PBC cases (358 in case 1 group and 201 in case 2 group) and 726 healthy controls of Chinese Han, six nonsynonymous SNPs were genotyped by MassArray iPLEX. The same control were used for the two groups of PBC cases. Allele frequencies were calculated by χ2 test based on 2 × 2 contingency tables. All data were analyzed using the PLINK tool set. The odds ratio (OR) and 95 % confidence interval (95 % CI) were calculated, and p values (corrected for multiple testing by Bonferroni adjustment) less than 0.05 were considered statistically significant.
Results
The A allele of rs79267778 was significantly associated with PBC (ORcombined = 4.204 [1.670–10.582], p combined = 1.87E−04). It changed the amino acid at position 1904 (NM_001037335) from Threonine (ACG) to Methionine (ATG). This site was highly conserved in mammals and predicted to be POSSIBLY DAMAGING with a score of 0.469 by PolyPhen-2. It’s further predicted that T1904 M could INCREASE the protein stability with a confidence at 25.18 % under the condition of pH 7.0 and 37 °C.
Conclusion
The result was the first time to show evidence of the lipid metabolic gene HELZ2 related to autoimmune disease, at least in PBC of Chinese Han.
Background
Primary biliary cirrhosis (PBC) is a common autoimmune liver disease, characteristically associated with anti-mitochondrial antibodies and affecting up to 1 in 1000 women over 40 years of age [1]. Though GWAS studies have found dozens of gene associated with PBC in European and Japanese populations. The genetic factors contributing to the pathogenesis still remain elusive.
HELZ2 [OMIM 611265], also known as PRIC285 or PDIP1, is a 2649 amino acid nuclear helicase protein, being a part of the peroxisome proliferator activated receptor α interacting (PRIC) complex [2]. It functions as a nuclear transcriptional coactivator for PPARA and PPARG, as well as other nuclear receptors (RXRA, THRA, THRB) [2, 3]. Inferred from items of gene ontology, this gene is mainly related with cellular lipid metabolic process [4] and liver regeneration [5].
It had been reported that HELZ2’s binding partner, Pparg could regulate the expression of inflammatory genes such as Ccl3, Ccl7, Cxcl10 and Tgtp in mice [6]. This gene also played an important role in innate immune responses [7] and related to immune-related diseases, such as HCV/HIV infection [8], osteoarthritis [9], acne vulgaris [10]. As to itself, HELZ2 possessed the ability to bind proteins important for immune responses, such as BCL6 [11] and ISG15 [12]. Therefore, we inferred that HELZ2 might be associated with autoimmune diseases. Since it could affect liver regeneration, this gene had the promising potentiality to contribute to the pathogenesis of PBC.
In order to verify the assumption, we selected 6 nonsynonymous SNPs in the coding region of HELZ2 from 1000 Genomes Project for Asian populations with MAF >2 % and genotyped in 586 PBC cases and 726 healthy controls with Chinese Han. Of the 6 SNPs, the T allele of rs79267778 was found to significantly associated with PBC (ORcombined = 4.204 [1.670−10.582], p combined = 1.87E−04). It changed the amino acid at position 1904 (NM_001037335) from Threonine (ACG) to Methionine (ATG). Conservation analysis showed this site was highly conserved in mammals and might influence the function of HELZ2. The result was the first time to show evidence of the lipid metabolic gene HELZ2 related to autoimmune disease, at least in PBC of Chinese Han.
Methods
Information of the recruited subjects
The peripheral blood mononuclear cells (PBMCs) of a total of 385 PBC subjects (case 1 group) and 726 age-matched healthy controls were collected by the Rheumatology Department of Peking Union Medical College Hospital and 201 PBC samples (case 2 group) collected from multiple medical centers in China (Table 1). The healthy control were used for the two groups of cases. All patients fulfilled the criteria of the American Association for the Study of Liver Diseases for primary biliary cirrhosis [13]. All patients and controls were unrelated individuals of Han Chinese ethnicity by self-report. The study was approved by the ethics committee of the Peking Union Medical College hospital and all subjects gave informed consent.
Genotyping of selected SNPs in HELZ2
The genomic DNA of each sample was extracted using QIAamp DNA mini kit (Qiagen, German), and SNP genotyping was performed by the MassArray iPLEX system (Sequenom, USA) at Beijing DnaLead Co. LTD. All procedures were performed according to the manufacturer’s instructions. Approximately 10 ng of genomic DNA was amplified by multiplex PCR and the amplicons subjected to locus-specific single-base extension reactions. The extended products were desalted and transferred to a 384-element SpectroCHIP array. Allele detection was performed using MALDI-TOF mass spectrometry, and the mass spectrograms were analyzed by the MassArray TYPER software v4.0 (Sequenom, USA). 6 SNPs in the coding sequence of HELZ2 were selected for genotyping in the 2 cohorts of Chinese Han (385 cases/726 controls and 201 cases/726 controls) by MassArray iPLEX.
Association analysis of the genotyped SNPs
The genotyped SNPs were tested for Hardy–Weinberg equilibrium (HWE) in the patient and control populations, and any SNPs that deviated from HWE (p < 0.05 in the control group) were excluded from subsequent analyses. Allele frequencies were calculated by χ2 test based on 2 × 2 contingency tables. Since the incidence of PBC was both gender and age related, we took gender and age as covariates in our analysis. All data were analyzed using the PLINK tool set. The odds ratio (OR) and 95 % confidence interval (95 % CI) were calculated, and p values (corrected for multiple testing by Bonferroni adjustment) less than 0.05 were considered statistically significant.
Results
Structural survey of the genomic region with HELZ2
We extracted structural variation data of the region (chr20:62,089,439-62,305,592) from the Database of Genomic Variants [14] and mapped against human reference genome (hg19). HELZ2 was encircled by common deletion polymorphisms. Besides, HELZ2 was located in a region with high recombination rate (cM/Mb) (Fig. 1, upper panel). The LD pattern showed that HELZ2 was in a weakly linked block (Fig. 1 lower panel). Based on these preliminary information, 6 nonsynonymous SNPs in the coding region of HELZ2 were selected from 1000 Genomes Project for Asian populations with MAF >2 % for further genotyping (Table 2).
Association of rs79267778 (T1904 M) with PBC in Chinese Han
Of the 6 nonsynonymous SNPs, five were successfully genotyped and one (rs114867526) failed. After analysis, only one SNP, rs79267778, was found to be significantly associated with PBC in the first cohort of PBC samples (358 cases/726 controls) (p = 3.62E−03). In order to validate the associatioin, 201 PBC samples from multiple medical centers were genotyped and compared with same control samples, rs79267778 was also marginally associated with the disease (p = 2.07E−02). After combination analysis, the SNP was strongerly linked with the pathognesis of PBC (ORcombined = 4.204 [1.670–10.582], p combined = 1.87E−04) (Table 2). rs79267778 located in the largest exon (E9) of HELZ2 (Fig. 2a). The risk allele (A allele) changed the amino acid at position 1904 (NP_001032412) from Threonine (ACG) to Methionine (ATG).
T1904 M was highly conserved in mammals
Sequences around rs79267778 of 14 species were extract and aligned by the molecular evolutionary genetics analysis software, MEGA v4.0 [15]. The first (A) and second (C) nucleotide of the codon for Threonine (ACG) was highly conserved, with the third varied greatly (Fig. 2b). This mutation was predicted to be POSSIBLY DAMAGING with a score of 0.469 by PolyPhen-2. The web-based software, MuStab (Predicting Mutant Protein Stability Change) was applied to predict if the SNP could influence the stability of HELZ2. Under the condition of pH 7.0 and 37 °C, T1904 M could INCREASE the protein stability with a confidence at 25.18 %.
Discussion
Previous GWAS had identified dozens of loci susceptible to primary biliary cirrhosis in European and Japanese population, such as HLA-DQB1, IL12A, IL12RB2, STAT4, SPIB, IRF5, IKZF3, IL7R, CD80, TNFSF15 and so on [16–19]. The majority of these genes participated in immune responses. Recently, the pivotal gene for energy metabolism, PPARG, has been linked with some kinds of immune-related diseases, such as HCV/HIV infection, osteoarthritis and acne vulgaris. As the important coactivator for PPARG, HELZ2 could bind proteins important for immune responses, such as BCL6 and ISG15. Therefore, we speculated that HELZ2 might be associated with autoimmune diseases. Since it could affect liver regeneration, HELZ2 had the highly potentiality to contribute to the pathogenesis of primary biliary cirrhosis.
Using a panel of 6 nonsynonymous SNPs of HELZ2 selected for association in 2 cohorts of Chinese Han, our results showed significant association of a rare SNP, rs79267778 with PBC in Han Chinese (ORcombined = 4.204 [1.670−10.582], p combined = 1.87E−04).
Recently, Fairfax B. reported that a known autoimmune disease locus, rs11171739 at 12q13.2 could trans-regulate the expression of PRIC285 (a well-known name for HELZ2) in B cells and suggested peroxisome proliferator-activated receptor γ (PPARG) signaling might be involved in autoimmune pathogenesis [20]. In this study, a nonsynonymous SNP in the coding region of HELZ2 was identified to significantly associated with PBC.This was the first genetic analysis to associate HELZ2 with the pathogenesis of autoimmune disease, at least for primary biliary cirrhosis in Han Chinese. Except for PBC, there are at lease 2 types of other autoimmune-related liver diseases, such as autoimmune hepatitis (AIH) and primary sclerosing cholangitis (PSC). The relationship of HELZ2 with AIH and PSC should be elucidated further.
Since rs79267778 could change the coding of amino acid at position 1904 of HELZ2, we inferred that it might affect the structure of DNA binding domain or transcription factor binding domain of the protein. According to the conserved domains of HELZ2, it contains 7 domains, AAA domain (519–590), DNA2 domain (642–938), UvrD_C_2 domain (713–915), P-loop_NTPase domain (2150–2189), AAA_11 domain (2152–2399), AAA_12 domain (2406–2611). T1904 M does not locate in any functional domains of the protein. The stability change of HELZ2 was predicted using MuStab for T1904 M. interestingly, the SNP could INCREASE the protein stability with a confidence at 25.18 %. The stabilized HELZ2 could prolong the half-life of its ligand-dependent nuclear receptor transcription coactivator activity. However, precise molecular mechanism of the variant of HELZ2 with primary biliary cirrhosis should be elucidated further.
Conclusion
This was the first evidence to show that the lipid metabolism-related gene, HELZ2 was linked with autoimmune disease, at least for primary biliary cirrhosis in Chinese Han population. Further studies should be performed to reveal the impact of this SNP on the function of HELZ2.
References
Kaplan MM, Gershwin ME. Primary biliary cirrhosis. New Engl J Med. 2005;353(12):1261–73.
Surapureddi S, Yu S, Bu H, Hashimoto T, Yeldandi AV, Kashireddy P, Cherkaoui-Malki M, Qi C, Zhu YJ, Rao MS, et al. Identification of a transcriptionally active peroxisome proliferator-activated receptor alpha-interacting cofactor complex in rat liver and characterization of PRIC285 as a coactivator. Proc Natl Acad Sci USA. 2002;99(18):11836–41.
Tomaru T, Satoh T, Yoshino S, Ishizuka T, Hashimoto K, Monden T, Yamada M, Mori M. Isolation and characterization of a transcriptional cofactor and its novel isoform that bind the deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma. Endocrinology. 2006;147(1):377–88.
Katano-Toki A, Satoh T, Tomaru T, Yoshino S, Ishizuka T, Ishii S, Ozawa A, Shibusawa N, Tsuchiya T, Saito T, et al. THRAP3 interacts with HELZ2 and plays a novel role in adipocyte differentiation. Mol Endocrinol. 2013;27(5):769–80.
Viswakarma N, Matsumoto K, Jia Y, Rao MS, Reddy JK. Mice lacking transcription cofactor PRIC285 reveal attenuation of liver regeneration but are viable and develop normally. FASEB J. 2009;23:117.
Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, Rose DW, Willson TM, Rosenfeld MG, Glass CK. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature. 2005;437(7059):759–63.
Berruyer C, Pouyet L, Millet V, Martin FM, LeGoffic A, Canonici A, Garcia S, Bagnis C, Naquet P, Galland F. Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor gamma activity. J Exp Med. 2006;203(13):2817–27.
Fernandez-Rodriguez A, Berenguer J, Rallon N, Jimenez-Sousa MA, Lopez JC, Soriano V, Garcia-Alvarez M, Cosin J, Martinez P, Guzman-Fulgencio M, et al. PPARgamma2 Pro12Ala polymorphism is associated with sustained virological response in HIV/HCV-coinfected patients under HCV therapy. J Acquir Immune Defic Syndr. 2014;67(2):113–9.
Zhang B, Xie QG, Quan Y, Pan XM. Expression profiling based on graph-clustering approach to determine osteoarthritis related pathway. Eur Rev Med Pharmacol Sci. 2013;17(15):2097–102.
Amr K, Abdel-Hameed M, Sayed K, Nour-Edin F, Abdel Hay R. The Pro12Ala polymorphism of the gene for peroxisome proliferator activated receptor-gamma is associated with a lower Global Acne Grading System score in patients with acne vulgaris. Clin Exp Dermatol. 2014;39(6):741–5.
Miles RR, Crockett DK, Lim MS, Elenitoba-Johnson KS. Analysis of BCL6-interacting proteins by tandem mass spectrometry. Mol Cell Proteom. 2005;4(12):1898–909.
Zhao C, Denison C, Huibregtse JM, Gygi S, Krug RM. Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. Proc Natl Acad Sci USA. 2005;102(29):10200–5.
Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology. 2000;31(4):1005–13.
MacDonald JR, Ziman R, Yuen RK, Feuk L, Scherer SW. The database of genomic variants: a curated collection of structural variation in the human genome. Nucl Acid Res. 2014;42:D986–92.
Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol. 2007;24(8):1596–9.
Nakamura M, Nishida N, Kawashima M, Aiba Y, Tanaka A, Yasunami M, Nakamura H, Komori A, Nakamuta M, Zeniya M, et al. Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. Am J Hum Genet. 2012;91(4):721–8.
Mells GF, Floyd JA, Morley KI, Cordell HJ, Franklin CS, Shin SY, Heneghan MA, Neuberger JM, Donaldson PT, Day DB, et al. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet. 2011;43(4):329–32.
Liu X, Invernizzi P, Lu Y, Kosoy R, Lu Y, Bianchi I, Podda M, Xu C, Xie G, Macciardi F, et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet. 2010;42(8):658–60.
Hirschfield GM, Liu X, Xu C, Lu Y, Xie G, Lu Y, Gu X, Walker EJ, Jing K, Juran BD, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. New Engl J Med. 2009;360(24):2544–55.
Fairfax BP, Makino S, Radhakrishnan J, Plant K, Leslie S, Dilthey A, Ellis P, Langford C, Vannberg FO, Knight JC. Genetics of gene expression in primary immune cells identifies cell type-specific master regulators and roles of HLA alleles. Nat Genet. 2012;44(5):502–10.
Authors' contributions
GL and YL conceived the project. GL designed the assays and experiments. PL and GL performed the experiments. PL, ZW, SC, JL, SL, YC and JL collected the samples and extracted genomic DNAs. GL wrote the paper. YL and GL supervised the procedure of this project and revised the manuscript. FZ and SM provided valuable discussion. GL, PL and LW contributed equally to the work. All authors read and approved the final manuscript.
Acknowledgements
We thank all participants recruited in this study. This work was supported by grants from the National Natural Science Foundation of China (81101490 to G. Lu, 81373188 to Y. Li, and 81172857 to Y. Li), Research Special Fund for Public Welfare Industry of Health (201202004 to Y. Li), the Chinese National High Technology Research and Development Program, Ministry of Science and Technology Grants (2011AA02A113 to Y. Li) and the National Science Technology Pillar Program in the 12nd Five-year Plan (2014BAI07B00 to Y. Li).
Competing interests
The authors declare that they no competing interests.
Author information
Authors and Affiliations
Corresponding author
Additional information
Ping Li, Guanting Lu and Li Wang equally contributed to this work
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Li, P., Lu, G., Wang, L. et al. A rare nonsynonymous variant in the lipid metabolic gene HELZ2 related to primary biliary cirrhosis in Chinese Han. Allergy Asthma Clin Immunol 12, 14 (2016). https://doi.org/10.1186/s13223-016-0120-6
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s13223-016-0120-6